Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

JNK targets p53 ubiquitination and degradation in nonstressed cells.

Fuchs SY, Adler V, Buschmann T, Yin Z, Wu X, Jones SN, Ronai Z.

Genes Dev. 1998 Sep 1;12(17):2658-63.

2.

Analysis of JNK, Mdm2 and p14(ARF) contribution to the regulation of mutant p53 stability.

Buschmann T, Minamoto T, Wagle N, Fuchs SY, Adler V, Mai M, Ronai Z.

J Mol Biol. 2000 Jan 28;295(4):1009-21.

PMID:
10656807
3.

MEKK1/JNK signaling stabilizes and activates p53.

Fuchs SY, Adler V, Pincus MR, Ronai Z.

Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10541-6.

4.

An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.

Midgley CA, Desterro JM, Saville MK, Howard S, Sparks A, Hay RT, Lane DP.

Oncogene. 2000 May 4;19(19):2312-23.

5.

Mdm2 association with p53 targets its ubiquitination.

Fuchs SY, Adler V, Buschmann T, Wu X, Ronai Z.

Oncogene. 1998 Nov 12;17(19):2543-7.

7.

c-Jun NH2-terminal kinases target the ubiquitination of their associated transcription factors.

Fuchs SY, Xie B, Adler V, Fried VA, Davis RJ, Ronai Z.

J Biol Chem. 1997 Dec 19;272(51):32163-8.

9.

The MDM2 ubiquitination signal in the DNA-binding domain of p53 forms a docking site for calcium calmodulin kinase superfamily members.

Craig AL, Chrystal JA, Fraser JA, Sphyris N, Lin Y, Harrison BJ, Scott MT, Dornreiter I, Hupp TR.

Mol Cell Biol. 2007 May;27(9):3542-55. Epub 2007 Mar 5.

11.
12.

The cytoprotective aminothiol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase.

Pluquet O, North S, Bhoumik A, Dimas K, Ronai Z, Hainaut P.

J Biol Chem. 2003 Apr 4;278(14):11879-87. Epub 2003 Jan 16.

13.

Characterization of sequence elements involved in p53 stability regulation reveals cell type dependence for p53 degradation.

Hengstermann A, Whitaker NJ, Zimmer D, Zentgraf H, Scheffner M.

Oncogene. 1998 Dec 3;17(22):2933-41.

14.

Conformation-dependent phosphorylation of p53.

Adler V, Pincus MR, Minamoto T, Fuchs SY, Bluth MJ, Brandt-Rauf PW, Friedman FK, Robinson RC, Chen JM, Wang XW, Harris CC, Ronai Z.

Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1686-91.

15.
16.

MDM2-dependent ubiquitination of nuclear and cytoplasmic P53.

Yu ZK, Geyer RK, Maki CG.

Oncogene. 2000 Nov 30;19(51):5892-7.

PMID:
11127820
17.
18.

Phosphorylation-dependent targeting of c-Jun ubiquitination by Jun N-kinase.

Fuchs SY, Dolan L, Davis RJ, Ronai Z.

Oncogene. 1996 Oct 3;13(7):1531-5.

PMID:
8875991
19.

Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation.

Zaika A, Marchenko N, Moll UM.

J Biol Chem. 1999 Sep 24;274(39):27474-80. Erratum in: J Biol Chem 2000 Apr 14;275(15):11538.

20.

Supplemental Content

Support Center